Most cancer drugs don’t actually kill cancer — they just slow it down.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, reveals why many FDA-approved cancer treatments are cytostatic, meaning they only halt tumor growth — not destroy it. The future, he says, is in cytotoxic precision oncology: treatments designed to actually kill cancer cells while sparing healthy ones.

Dr. Prato breaks down the crucial difference between managing and eliminating cancer, and explains why the immune system must be engaged for durable remissions. Using deep mapping tools like DNA, RNA, spatial biology, and immune profiling, Envita customizes therapies that combine precision targeting with immune activation — shifting the goal from “control” to “cure-driven remission.”

🎯 What You’ll Learn in This Episode:

• The real difference between cytostatic and cytotoxic drugs
• Why most new cancer drugs are designed to manage, not eliminate, disease
• How the immune system provides true cytotoxic killing power
• Why immunotherapy (PD-1s, NK cells) needs customization
• How deep mapping (DNA, RNA, spatial biology) reveals better treatment targets
• How Envita achieved up to 35x improved outcomes in late-stage patients*
  
  

📊 In published outcomes, precision oncology achieved up to 35x better responses and 43x improved quality of life by focusing on cytotoxic, immune-centered treatment algorithms.
*(See Outcomes Disclaimer Below)

“Managing cancer isn’t enough — it’s time to design care that actually kills it.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493